Ashish A. Kulkarni, Ph.D.
Affiliations: | 2011 | Chemistry | University of Cincinnati, Cincinnati, OH |
Area:
Biochemistry, Analytical ChemistryGoogle:
"Ashish Kulkarni"Parents
Sign in to add mentor| Suri S. Iyer | grad student | 2011 | University of Cincinnati | |
| (Tailored glycans for the precise detection of toxins and pathogens.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Kumar S, Ramesh A, Kulkarni A. (2020) Targeting macrophages: a novel avenue for cancer drug discovery. Expert Opinion On Drug Discovery. 1-14 |
| Ramesh A, Kumar S, Nguyen A, et al. (2020) Lipid-based phagocytosis nanoenhancer for macrophage immunotherapy. Nanoscale |
| Ramesh A, Natarajan SK, Nandi D, et al. (2019) Dual Inhibitors-Loaded Nanotherapeutics that Target Kinase Signaling Pathways Synergize with Immune Checkpoint Inhibitor. Cellular and Molecular Bioengineering. 12: 357-373 |
| Ramesh A, Brouillard A, Kumar S, et al. (2019) Dual inhibition of CSF1R and MAPK pathways using supramolecular nanoparticles enhances macrophage immunotherapy. Biomaterials. 227: 119559 |
| Ramesh A, Kumar S, Nandi D, et al. (2019) CSF1R- and SHP2-Inhibitor-Loaded Nanoparticles Enhance Cytotoxic Activity and Phagocytosis in Tumor-Associated Macrophages. Advanced Materials (Deerfield Beach, Fla.). e1904364 |
| Kulkarni A, Chandrasekar V, Natarajan SK, et al. (2018) A designer self-assembled supramolecule amplifies macrophage immune responses against aggressive cancer. Nature Biomedical Engineering. 2: 589-599 |
| Roy M, Krishna V, Sengupta A, et al. (2018) Abstract 4712: AT1965, a novel B cell-activating immunotherapy, exerts potent anticancer activity Cancer Research. 78: 4712-4712 |
| Ismail N, Kulkarni A, Kumar S, et al. (2017) Abstract 4610: Towards understanding the cellular uptake patterns of nano-particles among different immune cell lines Cancer Research. 77: 4610-4610 |
| Kulkarni A, Natarajan SK, Chandrasekar V, et al. (2016) Combining Immune Checkpoint Inhibitors and Kinase-Inhibiting Supramolecular Therapeutics for Enhanced Anti-Cancer Efficacy. Acs Nano |
| Goldman A, Kulkarni A, Kohandel M, et al. (2016) Rationally Designed 2-in-1 Nanoparticles Can Overcome Adaptive Resistance in Cancer. Acs Nano |